Cutaneous barriers in defense against microbial invasion

Skin Barrier

Volumn , Issue , 2005, Pages 363-377

  Di Nardo, Anna ^a   Gallo, Richard L ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 80755179488     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (69)

1. Mempel M, Schmidt T, Weidinger S, Schnopp C, Foster T, Ring J, Abeck D. Role of Staphylococcus aureus surface-associated proteins in the attachment to cultured HaCaT keratinocytes in a new adhesion assay. J Invest Dermatol 1998; 111(3):452-456.
2. Behrendt H, Green M. Nature of the sweating deficit of prematurely born neonates. Observations on babies with the heroin withdrawal syndrome. N Engl J Med 1972; 286(26):1376-1379.
3. Hardman MJ, Sisi P, Banbury DN, Byrne C. Patterned acquisition of skin barrier function during development. Development 1998; 125(8):1541-1552.
4. Visscher MO, Chatterjee R, Munson KA, Pickens WL, Hoath SB. Changes in diapered and nondiapered infant skin over the first month of life. Pediatr Dermatol 2000; 17(1):45-51.
5. Yosipovitch G, Maayan-Metzger A, Merlob P, Sirota L. Skin barrier properties in different body areas in neonates. Pediatrics 2000; 106(1 Pt 1):105-108.
6. Leyden JJ, Kligman AM. The role of microorganisms in diaper dermatitis. Arch Dermatol 1978; 114(1):56-59.
7. Aly R, Maibach HI, Rahman R, Shinefield HR, Mandel AD. Correlation of human in vivo and in vitro cutaneous antimicrobial factors. J Infect Dis 1975; 131(5):579-583.
8. Puhvel SM, Reisner RM, Sakamoto M. Analysis of lipid composition of isolated human sebaceous gland homogenates after incubation with cutaneous bacteria. Thin-layer chromatography. J Invest Dermatol 1975; 64(6):406-U1.
9. Bibel DJ, Aly R, Lahti L, Shinefield HR, Maibach HI. Microbial adherence to vulvar epithelial cells. J Med Microbiol 1987; 23(1):75-82.
10. Mauro T, Holleran WM, Grayson S, Gao WN, Man MQ, Kriehuber E, Behne M, Feingold KR, Elias PM. Barrier recovery is impeded at neutral pH, independent of ionic effects: implications for extracellular lipid processing. Arch Dermatol Res 1998; 290(4):215-222.
11. Takagi Y, Kriehuber E, Imokawa G, Elias PM, Holleran WM. Beta-glucocerebrosidase activity in mammalian stratum corneum. J Lipid Res 1999; 40(5):861-869.
12. Jensen JM, Schutze S, Neumann C, Proksch E. Impaired cutaneous permeability barrier function, skin hydration, and sphingomyelinase activity in keratin 10 deficient mice. J Invest Dermatol 2000; 115(4):708-713.
13. Schmuth M, Man MQ, Weber F, Gao W, Feingold KR, Fritsch P, Elias PM, Holleran WM. Permeability barrier disorder in Niemann-Pick disease: sphingomyelin-ceramide processing required for normal barrier homeostasis. J Invest Dermatol 2000; 115(3):459-466.
14. Holleran WM, Takagi Y, Menon GK, Legler G, Feingold KR, Elias PM. Processing of epidermal glucosylceramides is required for optimal mammalian cutaneous permeability barrier function. J Clin Invest 1993; 91(4):1656-1664.
15. Ament W, Huizenga JR, Mook GA, Gips CH, Verkerke GJ. Lactate and ammonia concentration in blood and sweat during incremental cycle ergometer exercise. Int J Sports Med 1997; 18(1):35-39.
16. Krien PM, Kermici M. Evidence for the existence of a self-regulated enzymatic process within the human stratum corneum -an unexpected role for urocanic acid. J Invest Dermatol 2000; 115(3):414-420.
17. Fluhr JW, Kao J, Jain M, Ahn SK, Feingold KR, Elias PM. Generation of free fatty acids from phospholipids regulates stratum corneum acidification and integrity. J Invest Dermatol 2001; 117(1):44-51.
18. Behne MJ, Meyer JW, Hanson KM, Barry NP, Murata S, Crumrine D, Clegg RW, Gratton E, Holleran WM, Elias PM, Mauro TM. NHE1 regulates the stratum corneum permeability barrier homeostasis. Microenvironment acidification assessed with fluorescence lifetime imaging. J Biol Chem 2002; 277(49):47399-47406.
19. Ushijima T, Takahashi M, Ozaki Y. Acetic, propionic, and oleic acid as the possible factors influencing the predominant residence of some species of Propionibacterium and coagulase-negative Staphylococcus on normal human skin. Can J Microbiol 1984; 30(5):647-652.
20. Elias PM, Brown BE, Ziboh VA. The permeability barrier in essential fatty acid deficiency: Evidence for a direct role for linoleic acid in barrier function. J Invest Dermatol 1984; 74:230-233.
21. Elias PM, Feingold KR. Coordinate regulation of epidermal differentiation and barrier homeostasis. Skin Pharmacol Appl Skin Physiol 2001; 14(Suppl 1):28-34.
22. Downing DT. Lipid and protein structures in the permeability barrier of mammalian epidermis. Journal of Lipid Research 1992; 33:301-313.
23. Wertz PW, Miethke MC, Long SA, Strauss JS, Downing DT. The composition of ceramides from human stratum corneum and from comedones. J Invest Dermatol 1985; 84:410-412.
24. Wertz PW, Downing DT. Acylglucosylceramides of pig epidermis: structure determination. J Lipid Res 1983; 24:753-758.
25. Yardley HJ, Summerly R. Lipid composition and metabolism in normal and diseased epidermis. Pharmacol Ther 1981; 13:357-381.
26. Bibel DJ, Miller SJ, Brown BE, Pandey BB, Elias PM, Shinefield HR, Aly R. Antimicrobial activity of stratum corneum lipids from normal and essential fatty acid-deficient mice. J Invest Dermatol 1989; 92(4):632-638.
27. Ganz T. Defensins: antimicrobial peptides of innate immunity. Nat Rev Immunol 2003; 3(9):710-720.
28. Fellermann K, Wehkamp J, Stange EF. Antimicrobial peptides in the skin. N Engl J Med 2003; 348(4):361-363.
29. Liu AY, Destoumieux D, Wong AV, Park CH, Valore EV, Liu L, Ganz T. Human beta-defensin-2 production in keratinocytes is regulated by interleukin-1, bacteria, and the state of differentiation. J Invest Dermatol 2002; 118(2):275-281.
30. Oren A, Ganz T, Liu L, Meerloo T. In human epidermis, beta-defensin 2 is packaged in lamellar bodies. Exp Mol Pathol 2003; 74(2):180-182.
31. Pernet I, Reymermier C, Guezennec A, Branka JE, Guesnet J, Perrier E, Dezutter-Dambuyant C, Schmitt D, Viac J. Calcium triggers beta-defensin (hBD-2 and hBD-3) and chemokine macrophage inflammatory protein-3 alpha (MIP-3alpha/CCL20) expression in monolayers of activated human keratinocytes. Exp Dermatol 2003; 12(6):755-760.
32. Sorensen OE, Cowland JB, Theilgaard-Monch K, Liu L, Ganz T, Borregaard N. Wound healing and expression of antimicrobial peptides/polypeptides in human keratinocytes, a consequence of common growth factors. J Immunol 2003; 170(11):5583-5589.
33. Dinulos JG, Mentele L, Fredericks LP, Dale BA, Darmstadt GL. Keratinocyte expression of human beta defensin 2 following bacterial infection: role in cutaneous host defense. Clin Diagn Lab Immunol 2003; 10(1):161-166.
34. Yang D, Chertov O, Oppenheim JJ. The role of mammalian antimicrobial peptides and proteins in awakening of innate host defenses and adaptive immunity. Cell Mol Life Sci 2001; 58(7):978-989.
35. Zanetti M. Cathelicidins, multifunctional peptides of the innate immunity. J Leukoc Biol 2004; 75(1):39-48.
36. Nizet V, Ohtake T, Lauth X, Trowbridge J, Rudisill J, Dorschner RA, Pestonjamasp V, Piraino J, Huttner K, Gallo RL. Innate antimicrobial peptide protects the skin from invasive bacterial infection. Nature 2001; 414(6862):454-457.
37. Di Nardo A, Vitiello A, Gallo RL. Cutting edge: mast cell antimicrobial activity is mediated by expression of cathelicidin antimicrobial peptide. J Immunol 2003; 170(5):2274-2278.
38. Sorensen OE, Gram L, Johnsen AH, Andersson E, Bangsboll S, Tjabringa GS, Hiemstra PS, Malm J, Egesten A, Borregaard N. Processing of seminal plasma hCAP-18 to ALL-38 by gastricsin: a novel mechanism of generating antimicrobial peptides in vagina. J Biol Chem 2003; 278(31):28540-28546.
39. Zanetti M, Gennaro R, Skerlavaj B, Tomasinsig L, Circo R. Cathelicidin peptides as candidates for a novel class of antimicrobials. Curr Pharm Des 2002; 8(9):779-793.
40. Howell MD, Jones JF, Kisich KO, Streib JE, Gallo RL, Leung DY. Selective killing of vaccinia virus by LL-37: implications for eczema vaccinatum. J Immunol 2004; 172(3):1763-1767.
41. Oren Z, Lerman JC, Gudmundsson GH, Agerberth B, Shai Y. Structure and organization of the human antimicrobial peptide LL-37 in phospholipid membranes: relevance to the molecular basis for its non-cell-selective activity. Biochem J 1999; 341(Pt 3):501-513.
42. Zaiou M, Nizet V, Gallo RL. Antimicrobial and protease inhibitory functions of the human cathelicidin (hCAP18/LL-37) prosequence. J Invest Dermatol 2003; 120 (5):810-816.
43. Dorschner RA, Lin KH, Murakami M, Gallo RL. Neonatal skin in mice and humans expresses increased levels of antimicrobial peptides: innate immunity during development of the adaptive response. Pediatr Res 2003; 53 (4):566-572.
44. Murakami M, Ohtake T, Dorschner RA, Schittek B, Garbe C, Gallo RL. Cathelicidin anti-microbial peptide expression in sweat, an innate defense system for the skin. J Invest Dermatol 2002; 119 (5):1090-1095.
45. Ong PY, Ohtake T, Brandt C, Strickland I, Boguniewicz M, Ganz T, Gallo RL, Leung DY. Endogenous antimicrobial peptides and skin infections in atopic dermatitis. N Engl J Med 2002; 347 (15):1151-1160.
46. Heilborn JD, Nilsson MF, Kratz G, Weber G, Sorensen O, Borregaard N, Stahle-Backdahl M. The cathelicidin anti-microbial peptide LL-37 is involved in re-epithelialization of human skin wounds and is lacking in chronic ulcer epithelium. J Invest Dermatol 2003; 120 (3):379-389.
47. Rot A, Von Andrian UH. Chemokines in Innate and Adaptive Host Defense: Basic Chemokinese Grammar for Immune Cells. Annu Rev Immunol 2004; 22:891-928.
48. Cole AM, Ganz T, Liese AM, Burdick MD, Liu L, Strieter RM. Cutting edge: IFN-inducible ELR- CXC chemokines display defensin-like antimicrobial activity. J Immunol 2001; 167 (2):623-627.
49. Modlin RL. Learning from leprosy: insights into contemporary immunology from an ancient disease. Skin Pharmacol Appl Skin Physiol 2002; 15 (1):1-6.
50. Canaday DH, Wilkinson RJ, Li Q, Harding CV, Silver RF, Boom WH. CD4 (+) and CD8 (+) T cells kill intracellular Mycobacterium tuberculosis by a perforin and Fas/ Fas ligand-independent mechanism. J Immunol 2001; 7 (5):2734-2742.
51. Ochoa MT, Stenger S, Sieling PA, Thoma-Uszynski S, Sabet S, Cho S, Krensky AM, Rollinghoff M, Nunes Sarno E, Burdick AE, Rea TH, Modlin RL. T-cell release of granulysin contributes to host defense in leprosy. Nat Med 2001; 7 (2):174-179.
52. Shimizu M, Shigeri Y, Tatsu Y, Yoshikawa S, Yumoto N. Enhancement ofantimicrobial activity of neuropeptide Y by N-terminal truncation. Antimicrob Agents Chemother 1998; 42 (10):2745-2746.
53. Lambert RW, Campton K, Ding W, Ozawa H, Granstein RD. Langerhans cell expression of neuropeptide Y and peptide YY. Neuropeptides 2002; 36 (4):246-251.
54. Cutuli M, Cristiani S, Lipton JM, Catania A. Antimicrobial effects of alpha-MSH peptides. J Leukoc Biol 2000; 67 (2):233-229.
55. Kew D, Kilpatrick DL. Widespread organ expression of the rat proenkephalin gene during early postnatal development. Mol Endocrinol 1990; 4 (2):337-340.
56. Metz-Boutigue MH, Kieffer AE, Goumon Y, Aunis D. Innate immunity: involvement of new neuropeptides. Trends Microbiol 2003; 11 (12):585-592.
57. Kapas S, Tenchini ML, Farthing PM. Regulation of adrenomedullin secretion in cultured human skin and oral keratinocytes. J Invest Dermatol 2001; 117 (2):353-359.
58. Muller FB, Muller-Rover S, Korge BP, Kapas S, Hinson JP, Philpott MP. Adrenomedullin: expression and possible role in human skin and hair growth. Br J Dermatol 2003; 148 (1):30-38.
59. Allaker RP, Zihni C, Kapas S. An investigation into the antimicrobial effects of adrenomedullin on members of the skin, oral, respiratory tract and gut microflora. FEMS Immunol Med Microbiol 1999; 23 (4):289-293.
60. Thompson RC, Ohlsson K. Isolation, properties, and complete amino acid sequence of human secretory leukocyte protease inhibitor, a potent inhibitor of leukocyte elastase. Proc Natl Acad Sci U S A 1986; 83 (18):6692-6696.
61. Fink E, Nettelbeck R, Fritz H. Inhibition of mast cell chymase by eglin c and antileukoprotease (HUSI-I). Indications for potential biological functions of these inhibitors. Biol Chem Hoppe Seyler 1986; 367 (7):567-571.
62. Franzke CW, Baici A, Bartels J, Christophers E, Wiedow O. Antileukoprotease inhibits stratum corneum chymotryptic enzyme. Evidence for a regulative function in desquamation. J Biol Chem 1996; 271 (36):21886-21890.
63. McNeely TB, Dealy M, Dripps DJ, Orenstein JM, Eisenberg SP, Wahl SM. Secretory leukocyte protease inhibitor: a human saliva protein exhibiting anti-human immunodeficiency virus 1 activity in vitro. J Clin Invest 1995; 96 (1):456-464.
64. Hiemstra PS, Maassen RJ, Stolk J, Heinzel-Wieland R, Steffens GJ, Dijkman JH. Antibacterial activity of antileukoprotease. Infect Immun 1996; 64 (11):4520-4524.
65. Darmstadt GL, Mentele L, Fleckman P, Rubens CE. Role of keratinocyte injury in adherence of Streptococcus pyogenes. Infect Immun 1999; 67 (12):6707-6709.
66. Ruiz N, Wang B, Pentland A, Caparon M. Streptolysin O and adherence synergistically modulate proinflammatory responses of keratinocytes to group A streptococci. Mol Microbiol 1998; 27 (2):337-346.
67. Freedberg IM, Tomic-Canic M, Komine M, Blumenberg M. Keratins and the keratinocyte activation cycle. J Invest Dermatol 2001; 116 (5):633-640.
68. Murakami M, Lopez-Garcia B, Braff M, Dorschner RA, Gallo RL. Postsecretory processing generates multiple cathelicidins for enhanced topical antimicrobial defense. J Immunol 2004; 172 (5):3070-3077.
69. Oppenheim JJ, Biragyn A, Kwak LW, Yang D. Roles of antimicrobial peptides such as defensins in innate and adaptive immunity. Ann Rheum Dis 2003; 62 (Suppl 2):ii17-ii21.